Challenges in Diagnosis and Therapeutic Strategies in Late-Onset Multiple Sclerosis

被引：4

作者：

Nociti, Viviana ^{[1
,2
]}

Romozzi, Marina ^{[2
]}

Mirabella, Massimiliano ^{[1
,2
]}

机构：

[1] Fdn Policlin Univ Agostino Gemelli IRCCS, Ctr Sclerosi Multipla, I-00168 Rome, Italy

[2] Univ Cattolica Sacro Cuore, Dipartimento Univ Neurosci, I-20123 Rome, Italy

来源：

JOURNAL OF PERSONALIZED MEDICINE | 2024年 / 14卷 / 04期

关键词：

late-onset multiple sclerosis; personalized medicine; disease-modifying therapies; comorbidities; ACUTE DISSEMINATED ENCEPHALOMYELITIS; CLINICAL CHARACTERISTICS; SUBGROUP ANALYSES; COMORBIDITY; AGE; PLACEBO; TRIAL; RISK; MRI; OCRELIZUMAB;

D O I：

10.3390/jpm14040400

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

Multiple sclerosis (MS) is a chronic inflammatory and degenerative demyelinating disease of the central nervous system of unknown etiology, which affects individuals in their early adulthood. However, nearly 5-10% of people with MS can be diagnosed at ages above 50 years old, referred to as late-onset multiple sclerosis (LOMS). Some studies have reported a distinctive presentation, clinical course, and prognosis for LOMS, implicating a different diagnostic and therapeutic approach for this population. Furthermore, similar manifestations between LOMS and other age-related conditions may lead to potential misdiagnosis and diagnostic delays, and a higher burden of multimorbidity associated with aging can further complicate the clinical picture. This review aims to explore the clinical characteristics, the disease course, and the differential diagnosis of LOMS and addresses therapeutic considerations for this population.

引用

页数：13

共 92 条

[21] Older Age at Multiple Sclerosis Onset Is an Independent Factor of Poor Prognosis: A Population-Based Cohort Study [J].

Guillemin, Francis ;

Baumann, Cedric ;

Epstein, Jonathan ;

Kerschen, Philippe ;

Garot, Teresa ;

Mathey, Guillaume ;

Debouverie, Marc .

NEUROEPIDEMIOLOGY, 2017, 48 (3-4) :179-187

[22] A global view of comorbidity in multiple sclerosis: a systematic review with a focus on regional differences, methodology, and clinical implications [J].

Hauer, Larissa ;

Perneczky, Julian ;

Sellner, Johann .

JOURNAL OF NEUROLOGY, 2021, 268 (11) :4066-4077

[23] Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis [J].

Hauser, S. L. ;

Bar-Or, A. ;

Comi, G. ;

Giovannoni, G. ;

Hartung, H. -P. ;

Hemmer, B. ;

Lublin, F. ;

Montalban, X. ;

Rammohan, K. W. ;

Selmaj, K. ;

Traboulsee, A. ;

Wolinsky, J. S. ;

Arnold, D. L. ;

Klingelschmitt, G. ;

Masterman, D. ;

Fontoura, P. ;

Belachew, S. ;

Chin, P. ;

Mairon, N. ;

Garren, H. ;

Kappos, L. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (03) :221-234

[24] The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL [J].

Hutchinson, Michael ;

Kappos, Ludwig ;

Calabresi, Peter A. ;

Confavreux, Christian ;

Giovannoni, Gavin ;

Galetta, Steven L. ;

Havrdova, Eva ;

Lublin, Fred D. ;

Miller, David H. ;

O'Connor, Paul W. ;

Phillips, J. Theodore ;

Polman, Chris H. ;

Radue, Ernst-Wilhelm ;

Rudick, Richard A. ;

Stuart, William H. ;

Wajgt, Andrzej ;

Weinstock-Guttman, Bianca ;

Wynn, Daniel R. ;

Lynn, Frances ;

Panzara, Michael A. .

JOURNAL OF NEUROLOGY, 2009, 256 (03) :405-415

[25] High risk of cardiovascular diseases after diagnosis of multiple sclerosis [J].

Jadidi, Elham ;

Mohammadi, Mohammad ;

Moradi, Tahereh .

MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (10) :1336-1340

[26] Considering patient age when treating multiple sclerosis across the adult lifespan [J].

Jakimovski, Dejan ;

Eckert, Svetlana P. ;

Zivadinov, Robert ;

Weinstock-Guttman, Bianca .

EXPERT REVIEW OF NEUROTHERAPEUTICS, 2021, 21 (03) :353-364

[27] CNS Vasculitis-An Overview of This Multiple Sclerosis Mimic: Clinical and MRI Implications [J].

Jewells, Valerie L. ;

Latchaw, Richard E. .

SEMINARS IN ULTRASOUND CT AND MRI, 2020, 41 (03) :296-308

[28] Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years [J].

Kalincik, Tomas ;

Diouf, Ibrahima ;

Sharmin, Sifat ;

Malpas, Charles ;

Spelman, Tim ;

Horakova, Dana ;

Havrdova, Eva Kubala ;

Trojano, Maria ;

Izquierdo, Guillermo ;

Lugaresi, Alessandra ;

Prat, Alexandre ;

Girard, Marc ;

Duquette, Pierre ;

Grammond, Pierre ;

Jokubaitis, Vilija ;

Van der Walt, Anneke ;

Grand'Maison, Francois ;

Sola, Patrizia ;

Ferraro, Diana ;

Shaygannejad, Vahid ;

Alroughani, Raed ;

Hupperts, Raymond ;

Terzi, Murat ;

Boz, Cavit ;

Lechner-Scott, Jeannette ;

Pucci, Eugenio ;

Van Pesch, Vincent ;

Granella, Franco ;

Bergamaschi, Roberto ;

Spitaleri, Daniele ;

Slee, Mark ;

Vucic, Steve ;

Ampapa, Radek ;

McCombe, Pamela ;

Ramo-Tello, Cristina ;

Prevost, Julie ;

Olascoaga, Javier ;

Cristiano, Edgardo ;

Barnett, Michael ;

Saladino, Maria Laura ;

Sanchez-Menoyo, Jose Luis ;

Hodgkinson, Suzanne ;

Rozsa, Csilla ;

Hughes, Stella ;

Moore, Fraser ;

Shaw, Cameron ;

Butler, Ernest ;

Skibina, Olga ;

Gray, Orla ;

Kermode, Allan .

NEUROLOGY, 2021, 96 (05) :E783-E797

[29] Cardiovascular Dysfunction in Multiple Sclerosis [J].

Kaplan, Tamara B. ;

Berkowitz, Aaron L. ;

Samuels, Martin A. .

NEUROLOGIST, 2015, 20 (06) :108-114

[30] Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study [J].

Kappos, Ludwig ;

Bar-Or, Amit ;

Cree, Bruce A. C. ;

Fox, Robert J. ;

Giovannoni, Gavin ;

Gold, Ralf ;

Vermersch, Patrick ;

Arnold, Douglas L. ;

Arnould, Sophie ;

Scherz, Tatiana ;

Wolf, Christian ;

Wallstroem, Erik ;

Dahlke, Frank .

LANCET, 2018, 391 (10127) :1263-1273

← 1 2 3 4 5 6 7 8 9 10 →